Insider Buying: Anixa Biosciences (NASDAQ:ANIX) CEO Purchases $17,350.00 in Stock

Anixa Biosciences Inc (NASDAQ:ANIX) CEO Amit Kumar purchased 5,000 shares of the company’s stock in a transaction on Friday, July 31st. The stock was acquired at an average cost of $3.47 per share, for a total transaction of $17,350.00. Following the completion of the transaction, the chief executive officer owned 657,000 shares in the company, valued at approximately $2,279,790. This trade represents a 0.77% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link.

Amit Kumar also recently made the following trade(s):

• On Friday, July 24th, Amit Kumar acquired 3,000 shares of Anixa Biosciences stock. The stock was acquired at an average cost of $3.73 per share, with a total value of $11,190.00.
• On Monday, July 20th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was bought at an average price of $3.46 per share, for a total transaction of $17,300.00.
• On Monday, July 27th, Amit Kumar bought 3,188 shares of Anixa Biosciences stock. The shares were bought at an average cost of $3.37 per share, for a total transaction of $10,743.56.
• On Monday, July 27th, Amit Kumar purchased 5,000 shares of Anixa Biosciences stock. The shares were purchased at an average price of $3.44 per share, for a total transaction of $17,200.00.
• On Friday, July 10th, Amit Kumar acquired 5,000 shares of Anixa Biosciences stock. The stock was acquired at an average price of $3.04 per share, with a total value of $15,200.00.
• On Friday, June 12th, Amit Kumar bought 21,000 shares of Anixa Biosciences stock. The shares were bought at an average price of $2.50 per share, with a total value of $52,500.00.

Anixa Biosciences Stock Performance

Shares of NASDAQ:ANIX opened at $3.41 on Thursday. Anixa Biosciences Inc has a 52 week low of $2.32 and a 52 week high of $5.46. The company has a market capitalization of $116.02 million, a PE ratio of -11.00 and a beta of 0.55. The company’s fifty day moving average is $3.01 and its 200-day moving average is $2.93.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Wednesday, June 10th. The company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.03. On average, analysts forecast that Anixa Biosciences Inc will post -0.31 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on ANIX. HC Wainwright restated a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. Wall Street Zen upgraded shares of Anixa Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, June 20th. D. Boral Capital reissued a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a report on Tuesday, June 30th. Zacks Research upgraded shares of Anixa Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Finally, Citigroup reaffirmed a “buy” rating on shares of Anixa Biosciences in a research note on Friday, June 12th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat, Anixa Biosciences has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Institutional Investors Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in ANIX. NewEdge Advisors LLC bought a new position in Anixa Biosciences in the second quarter valued at about $33,000. Cetera Investment Advisers bought a new stake in Anixa Biosciences during the 4th quarter worth about $35,000. Northwestern Mutual Wealth Management Co. raised its holdings in Anixa Biosciences by 2,000.0% during the 3rd quarter. Northwestern Mutual Wealth Management Co. now owns 10,500 shares of the company’s stock worth $35,000 after purchasing an additional 10,000 shares during the last quarter. Benjamin Edwards Inc. acquired a new position in Anixa Biosciences during the 2nd quarter valued at about $37,000. Finally, Millennium Management LLC acquired a new position in Anixa Biosciences during the 4th quarter valued at about $38,000. 29.13% of the stock is owned by institutional investors and hedge funds.

Anixa Biosciences Company Profile

Anixa Biosciences is a clinical-stage immuno-oncology and infectious disease company developing novel cell-based immunotherapies and vaccine platforms. Through its Anixa Therapeutics division, the company is advancing antibody and T-cell modalities, including an ovarian cancer immunotherapy candidate and a COVID-19 vaccine leveraging a proprietary virus-like particle (VLP) technology. Its research pipeline emphasizes modular vaccine design and personalized cancer cell therapy aimed at inducing durable immune responses against solid tumors.

In parallel, Anixa Diagnostics is developing the ADAPT diagnostic platform, a high-throughput proteomics approach using engineered peptides derived from spider venom.